Name | Ensituximab |
---|
Description | Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer[1][2]. |
---|---|
Related Catalog | |
In Vitro | Ensituximab (NPC-1C) 是一种嵌合 IgG1 单克隆抗体,在结合其靶标后促进抗体依赖性细胞的细胞毒性,MUC5AC 是一种肿瘤特异性变体,一种由结直肠癌 (CRC) 和胰腺癌特异性表达的抗原[1]。 |
References |
No Any Chemical & Physical Properties |